Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation.
Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation.
复制标题
DOI：
10.1016/j.jhep.2010.10.004
复制
发表时间：
2011-04
影响因子：
25.7
通讯作者：
Salem, Riad
中科院分区：
文献类型：
--
作者：
Riaz, Ahsun;Memon, Khairuddin;Miller, Frank H.;Nikolaidis, Paul;Kulik, Laura M.;Lewandowski, Robert J.;Ryu, Robert K.;Sato, Kent T.;Gates, Vanessa L.;Mulcahy, Mary F.;Baker, Talia;Wang, Ed;Gupta, Ramona;Nayar, Ritu;Benson, Al B., III;Abecassis, Michael;Omary, Reed;Salem, Riad
我们试图研究欧洲肝脏研究协会（EASL）的接受者-操作特征（ROC）、实体肿瘤反应评价标准（RECIST）和世界卫生组织（WHO）评估局部区域单独治疗和各种组合治疗后反应的指南。81例肝癌患者在局部治疗后行肝移植。采用EASL、RECIST和WHO评估反应。Kappa统计用于确定方法间的一致性。进行单因素/多因素logistic回归分析以确定预测完全病理性坏死的变量。对反应等级进行数值划分：完全反应=0，部分反应=1，病情稳定=2，病情进展=3。以外植体病理检查为金标准，测定EASL和WHO的各种数学组合计算得分，并研究其roc。对WHO、RECIST和EASL反应的中位时间（95% CI）分别为5.3（4-11.5）、5.6（4-11.5）和1.3个月（1.2-1.5）。WHO/RECIST、WHO/EASL和RECIST/EASL的Kappa系数分别为0.78、0.28和0.31。单因素/多因素分析表明，EASL反应在预测完全病理性坏死方面具有显著的优势比。ROC曲线下计算面积为：RECIST: 0.63, WHO: 0.68, EASL: 0.82, EASL+WHO: 0.82, EASLxWHO: 0.85, EASL+(2xWHO): 0.79, (2xEASL)+WHO: 0.85。EASLxWHO评分≤1对预测完全病理性坏死的敏感性为90.2%。WHO与EASL的乘积在评估肿瘤反应方面表现出较好的ROC。EASLxWHO评分系统为肝细胞癌局部治疗后的疗效评估提供了一种简单且临床适用的方法。
We sought to study receiver-operating characteristics (ROC) of the European Association for the Study of the Liver (EASL), Response Evaluation Criteria in Solid Tumors (RECIST) and World Health Organization (WHO) guidelines of assessing response following locoregional therapies individually and in various combinations. Eighty-one patients with hepatocellular carcinoma underwent liver explantation following locoregional therapies. Response was assessed using EASL, RECIST and WHO. Kappa statistics were used to determine inter-method agreement. Uni/multivariate logistic regression analyses were performed to determine the variables predicting complete pathologic necrosis. Numerical values were assigned to the response classes: complete response=0, partial response=1, stable disease=2 and progressive disease=3. Various mathematical combinations of EASL and WHO were tested to calculate scores and their ROCs were studied using pathological examination of the explant as the gold standard. Median times (95% CI) to WHO, RECIST and EASL response were 5.3 (4–11.5), 5.6 (4–11.5) and 1.3 months (1.2–1.5) respectively. Kappa coefficients for WHO/RECIST, WHO/EASL and RECIST/EASL were 0.78, 0.28 and 0.31 respectively. EASL response demonstrated significant odds ratios for predicting complete pathologic necrosis on uni/multivariate analyses. Calculated areas under the ROC curves were: RECIST: 0.63, WHO: 0.68, EASL: 0.82, EASL+WHO: 0.82, EASLxWHO: 0.85, EASL+(2xWHO): 0.79 and (2xEASL)+WHO: 0.85. An EASLxWHO Score of ≤ 1 had 90.2% sensitivity for predicting complete pathologic necrosis. The product of WHO and EASL demonstrated better ROC than the individual guidelines for assessment of tumor response. The EASLxWHO Scoring System provides a simple and clinically applicable method of response assessment following locoregional therapies for hepatocellular carcinoma.
登录
查看更多内容
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
DOI：
10.1016/j.jvir.2006.10.005
发表时间：
2007-01-01
影响因子：
2.9
作者：
Kamel, Ihab R.;Reyes, Diane K.;Geschwind, Jean-Francois H.
通讯作者：
Geschwind, Jean-Francois H.
影响因子：
45.3
作者：
Choi, Haesun;Charnsangavej, Chuslip;Benjamin, Robert S.
通讯作者：
Benjamin, Robert S.
影响因子：
158.5
作者：
Llovet, Josep M.;Ricci, Sergio;Bruix, Jordi
通讯作者：
Bruix, Jordi
影响因子：
4.6
作者：
Maddala, YK;Stadheim, L;Gores, G
通讯作者：
Gores, G